Avalo Therapeutics - AVTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$15.24
▲ +0.34 (2.28%)

This chart shows the closing price for AVTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avalo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.24.

This chart shows the closing price for AVTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Avalo Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2023OppenheimerDowngradeOutperform ➝ Market PerformLow
6/27/2023Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformLow
2/8/2023Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
11/15/2022OppenheimerLower Target$2,400.00N/A
11/9/2022OppenheimerLower Target$4,080.00 ➝ $2,400.00Low
7/11/2022Royal Bank of CanadaLower Target$5,760.00 ➝ $5,040.00N/A
3/3/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$14,400.00 ➝ $2,160.00High
3/3/2022Royal Bank of CanadaLower TargetOutperform$14,400.00 ➝ $11,520.00High
1/7/2022OppenheimerReiterated RatingBuy$14,400.00High
9/24/2021Royal Bank of CanadaInitiated CoverageOutperform$17,280.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Avalo Therapeutics logo
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $15.24
Low: $14.54
High: $15.69

50 Day Range

MA: $7.79
Low: $4.20
High: $21.75

52 Week Range

Now: $15.24
Low: $3.95
High: $1,130.40

Volume

91,326 shs

Average Volume

591,368 shs

Market Capitalization

$15.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Avalo Therapeutics?

The following sell-side analysts have issued reports on Avalo Therapeutics in the last twelve months: Oppenheimer Holdings Inc., and Royal Bank of Canada.
View the latest analyst ratings for AVTX.

What is the current price target for Avalo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Avalo Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Avalo Therapeutics in the next year.
View the latest price targets for AVTX.

What is the current consensus analyst rating for Avalo Therapeutics?

Avalo Therapeutics currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AVTX, but not buy more shares or sell existing shares.
View the latest ratings for AVTX.

What other companies compete with Avalo Therapeutics?

How do I contact Avalo Therapeutics' investor relations team?

Avalo Therapeutics' physical mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The company's listed phone number is (410) 522-8707 and its investor relations email address is [email protected]. The official website for Avalo Therapeutics is www.avalotx.com. Learn More about contacing Avalo Therapeutics investor relations.